Calidi Biotherapeutics effects 1-for-12 reverse stock split effective August 4, 2025

Calidi Biotherapeutics, Inc.

Reverse stock split at ratio 1-for-12 became effective on August 4, 2025.
No fractional shares issued; rounding up to nearest whole share; authorized shares unchanged at 330M common, 1M preferred.
Stock continues trading under symbol CLDI on NYSE American with new CUSIP 320703408.
Company states reverse split aims to optimize market dynamics and broaden investor appeal.
All outstanding equity awards adjusted proportionally to reflect the reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Calidi Biotherapeutics, Inc.: Approved a 1-for-12 reverse stock split via Certificate of Amendment to the Certificate of Incorporation (effective 2025-08-04).

Change: charter amendment
Effective: 2025-08-04

Exact text from the filing

The Reverse Stock Split was effected pursuant to the Company’s filing of a Certificate of Amendment (the “Certificate”) with the Secretary of State of the State of Delaware.

View on SEC.gov

Browse all governance changes →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-022592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.